-
Mayo Clinic Discovery Leads to FDA Approval for Stem Cell Trial for Heart Failure Patients
Share this:
U.S. FDA Approves Phase III Cardiopoietic Stem Cell Trial for Heart Failure Patients Based on a Mayo Discovery
Cardio3 BioSciences, an international Mayo Clinic collaborator, has received FDA approval for a phase III pivotal clinical trial of its stem cell therapy. The trial will test the Mayo Clinic discovery of cardiopoietic (cardiogenically-instructed) stem cells designed to improve heart health in people suffering from heart failure. The multisite U.S. trial, called CHART-2, will aim to recruit 240 patients with chronic advanced symptomatic heart failure. Cardio3 BioSciences is a bioscience company in Mont-Saint-Guibert, Belgium.
"Regenerative medicine is poised to transform the way we treat patients," says Andre Terzic, M.D., Ph.D., director of the Mayo Clinic Center for Regenerative Medicine. Watch the video below to see how stem cells are being used to treat people with heart failure.
Journalists: Video b-roll of today's news conference, plus sound bites with Dr. Terzic and Christian Homsy, M.D., CEO of Cardio3 BioSciences, are available in the downloads. The video pkg. is also available in the downloads in MOV format.
https://www.youtube.com/watch?v=vumB_FW_fTA
Share this:
Related articles
ROCHESTER, Minn. — Patients who received the anticoagulant drug warfarin after bioprosthetic aortic valve replacement had lower incidence of mortality and a decreased risk of ...
ROCHESTER, Minn. — Heart failure is a potentially urgent health concern for young adults with congenital heart disease (ACHD) that is often overlooked and undertreated, ...
Mayo Clinic doctors are using innovation to improve the lives of people who suffer from congestive heart failure and other chronic heart conditions. The Organ ...